Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- Lockheed Martin to acquire Ultra Maritime for $3.45 billion
Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
November 2, 2020 4:05 PM ESTWALTHAM, Mass., Nov. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2020. In addition, the Company provided a clinical and business update.
"We continue to make exciting progress in the Phase 1 portion of the AUGMENT-101 trial of SNDX-5613, our highly selective, potent, oral menin inhibitor, in adult and pediatric patients with acute leukemias that harbor MLL-r and NPM1 genetic alterations," said... More
